How many investments has GENERAL INCEPTION made?

GENERAL INCEPTION has 42 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.

What stage does GENERAL INCEPTION invest at?

GENERAL INCEPTION invests at the Pre-Seed, Seed stages.

What sectors does GENERAL INCEPTION focus on?

GENERAL INCEPTION focuses on Biotech, Deep Tech, Medical Devices, Sector Agnostic.

Where is GENERAL INCEPTION located?

GENERAL INCEPTION is headquartered in Palo Alto, US.

Does GENERAL INCEPTION lead rounds?

GENERAL INCEPTION typically participates in rounds rather than leading them.

GENERAL INCEPTION

Venture studiooperating company · company profile

Palo Alto · Pre-Seed–Seed · 44 people tracked

Also known as GENERAL INCEPTION MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into GENERAL INCEPTION

3,165 people in our graph share verified history with the GENERAL INCEPTION team — schools, employers, funds. One of them is your warm intro.

Sundeep Peechuunlockedknows Paul Conley · together at Ginkgo Bioworks (overlapped)

×2knows the team · via Anomali

×4knows the team · via McKinsey & Company

knows the team · via Techstars

knows the team · via HEC Paris

knows the team · via Vista Equity Partners

✨ Fox Verdict

Investment thesis

General Inception acts as a business co-founder for scientific and technical entrepreneurs building science-based companies. Its model centers on assembling the right people, customers, and funding partners at the optimal time for company formation and growth. GI supports founders across legal, financial, business strategy, and operational challenges, partnering through company formation, product development, and institutional fundraising. Its portfolio forms an interconnected ecosystem that shares access to new technologies, customers, and markets. The firm focuses on translating deep tech visions into customer-facing businesses, guiding founders from initial idea through seed-stage investment and beyond.

Invests inBiotech Deep Tech Medical DevicesSector AgnosticPalo Alto

Source: firm website, verified Sep 15, 2026.

Stage

Pre-Seed–Seed

Palo Alto, CA, US

Leads rounds

Follows

Instruments

Equity

Founded

2019

Last 12 months

1 investment

Private fund assets

$52.2M

VC funds

Tracked investments

Acquisitions

Team · 44 people

from the firm's website & curated & public directories

Paul Conley· Chairman & CEO· Palo Alto, California, United Statesin 𝕏

Paul Conley is CEO and co-founder of General Inception, an organization focused on company formation for deep-tech and life-science startups. General Inception operates as an institutional co-founder to technical founders and invests capital from its own balance sheet rather than functioning as a venture capital firm.

p•••@vvp.vcreveal

Camela Wilson· General Partner

Craig Asher· General Partner

Vikram Chaudhery· President & COO· San Francisco, Californiain 𝕏

Vikram Chaudhery is founder and president of General Inception and a partner at Genoa Ventures, focusing on life sciences investments. His background includes work with Fortune 500 and 1000 pharmaceutical and biotechnology companies in M&A, R&D, and commercial strategy, with particular expertise in diagnostics sales, operations, and growth. His investment interests center on genomics, proteomics, and metabolomics.

v•••@genoavc.comreveal

Adam Weischhaus· Executive in Residence, Life Science Tools & Dx

Alan Dance· Executive in Residence, Life Science Tools & Dx· Saratoga, California, United Statesin

a•••@generalinception.comreveal

Arunan Skandarajah· Executive in Residence, Life Science Tools & Dx· Washington, District of Columbia, United Statesin

Arunan Skandarajah is an independent technical and management consultant focused on medical product strategy, R&D, and commercialization. His background spans research at UC Berkeley, malaria elimination work at the Gates Foundation, corporate strategy at McKinsey, and roles at the FDA, and he has invested as an impact investor in areas including point-of-care ultrasound in Sub-Saharan Africa and automated diagnostics manufacturing. At ARPA-H, he joined as a Presidential Innovation Fellow supporting a White House biomedical initiative, contributed to building the agency as it grew to over 300 staff, and managed its SBIR program.

Autumn Lee· Chief of Staff· San Francisco Bay Areain

Autumn Lee serves as Chief of Staff at General Inception and is President-Elect of the PDA West Coast Chapter. She has experience managing venture programs and leading projects across clinical and commercial supply organizations, with a focus on translating innovative life sciences technologies into scalable companies through global collaboration with executives and entrepreneurs.

a•••@generalinception.comreveal

Brad Crutchfield· Executive in Residence, Life Science Tools & Dx· United Statesin

b•••@generalinception.comreveal

Brad Nelson· Division Lead, Life Science Tools & Dx· San Francisco, California, United Statesin

Brad Nelson is Chief Executive Officer of Enable Medicine, a company focused on a translational data layer for AI-powered drug development. His background covers investing and operating roles across life science tools, diagnostics, and medical device sectors, including company creation, portfolio strategy, and CEO and board leadership. His work involves shaping strategy, building leadership teams, and coordinating product, capital, and go-to-market execution.

b•••@generalinception.comreveal

Byron Hewett· Executive in Residence, Life Science Tools & Dx· Boulder, Colorado, United Statesin

b•••@generalinception.comreveal

Carol Tillis· Finance· San Jose, California, United Statesin

Carol Tillis is Vice President of Finance at General Inception. Her experience spans finance, accounting, auditing, FP&A, financial modeling, and investor relations, including areas such as GAAP and SOX compliance, system integrations, revenue recognition, equity accounting, SEC filings, and month-end closes. She has also worked with boards, audit committees, and external auditors.

c•••@generalinception.comreveal

Chris Barbazette· Executive in Residence, Life Science Tools & Dx· United Statesin

Chris Barbazette is an Executive in Residence at General Inception. His background includes leading commercial functions across markets in the Americas, Asia, the Middle East, and Africa, with experience in both emerging and mature markets. His areas of work include direct sales team management, distribution management, outbound marketing, product management, and service and support leadership.

c•••@generalinception.comreveal

Christopher Hoppe· Vice President· San Francisco, Californiain

Christopher Hoppe is Vice President, Investor, and Co-Builder at General Inception. He brings 20 years of experience in operations and corporate strategy across startups and multinational corporations, with particular expertise in life sciences, biotech, and healthcare sectors. His background includes leading product launches, managing M&A transactions exceeding $300 million, implementing operational plans, and conducting quantitative risk assessments for large organizations.

c•••@generalinception.comreveal

David Ferrick· Executive in Residence, Engineered Biology· Greater Sacramentoin

David Ferrick is Chief Executive Officer of Moddik Inc., a company focused on life science tools and immunotherapy. He has more than 20 years of experience in the biotechnology sector, working across drug discovery, strategic partnerships, and the commercialization of life science products in areas including immunology, cancer, neurological diseases, and cell and gene therapy. His work has included advancing drug development programs and in vitro diagnostic tests.

David Klein· Executive in Residence, Life Science Tools & Dx· Mountain View, California, United Statesin

Elisabeth Gardiner· Strategic Advisor· Boston, Massachusetts, United Statesin

e•••@generalinception.comreveal

Elodie Dormes· Business Development· Greater Marseille Metropolitan Areain

e•••@generalinception.comreveal

Francois Valencony· Chief Business Officer· Caluire-et-Cuire, Auvergne-Rhône-Alpes, Francein

Greg Timblin· Executive in Residence, Therapeutics· Berkeley, California, United Statesin

Greg Timblin is CEO and co-founder of Inapill, a company developing therapeutics that target immune cell metabolism to treat age-related chronic inflammatory and autoimmune diseases. He holds B.S. degrees in Chemistry and Biology from Nebraska Wesleyan University and a Ph.D. in Molecular and Cell Biology from UC Berkeley, and completed postdoctoral research at UC Berkeley and UCSF studying proinflammatory gene expression and metabolic-epigenetic pathways in the immune system. He co-founded Inapill with Josh Farahzad; the company is supported by venture studio General Inception and operates out of Bakar Bio Labs on the UC Berkeley campus.

g•••@generalinception.comreveal

Ingrid Caton· Program Manager· Vacaville, California, United Statesin

Ingrid Caton is a Project Director at General Inception with over 18 years of experience in program management within regulated diagnostics, IVD, biotech, and medical device settings. She has established portfolio governance, KPIs, delivery frameworks, and risk management systems, working across R&D, Engineering, Marketing, Supply Chain, Commercial, Regulatory, and Quality functions. Her background includes new product introductions on the Bio-Rad BioPlex 2200 platform and compliance with standards such as FDA, ISO 13485, ISO 14971, MDSAP, and IVDR.

i•••@generalinception.comreveal

Jeff Caputo· Executive in Residence, Life Science Tools & Dx· Winchester, Massachusetts, United Statesin

Jeff Caputo is President, CEO, and a Board Member at ClearCut Surgical. He has over 20 years of experience in the life sciences industry, spanning sales, marketing, business development, general management, operations, strategy, clinical research, and product development.

j•••@generalinception.comreveal

Jeff Rieger· Executive in Residence, Life Science Tools & Dx· Cambridge, Massachusetts, United Statesin

j•••@generalinception.comreveal

John Leonard· Executive in Residence, Therapeutics· United Statesin

John Leonard is an Entrepreneur in Residence at General Inception and works as a scientist, chief scientific officer, and R&D consultant. He has over 25 years of R&D experience spanning therapeutic modalities including small molecules, biologics, and cell and gene therapies, as well as disease areas such as autoimmune/inflammatory conditions, immuno-oncology, and rare diseases. His work has included advancing programs from discovery through early clinical development and proof of concept.

j•••@generalinception.comreveal

John Saunders· Business Operations

j•••@generalinception.comreveal

Kelli Zimmerman· Administrative Staff· Thornton, Colorado, United Statesin

k•••@generalinception.comreveal

Larry Burgess· Executive in Residence, Therapeutics· St Augustine, Florida, United Statesin

l•••@generalinception.comreveal

Laure Bouchez· Executive in Residence, Therapeutics· Allschwil, Basel-Country, Switzerlandin

Laure Bouchez is an Executive in Residence at General Inception with over 14 years of experience in the pharmaceutical industry. Her work in drug discovery includes an inventorship role in identifying six clinical candidates, two of which reached Phase I/II and one of which is on the market, along with 40 publications and eight published patents. She has managed cross-functional teams of up to 21 scientists, received the 2012 European Federation for Medicinal Chemistry "Young Medicinal Chemist in Industry" award, and has tutored at Oxford and Bern.

l•••@generalinception.comreveal

Loïc Vincent· Strategic Advisor· Toulon, Provence-Alpes-Côte d'Azur, France

l•••@generalinception.comreveal

Marsha Hartman· Executive in Residence, Life Science Tools & Dx· Phoenix, Arizona, United Statesin

Marsha Hartman is a board member at FlowView Diagnostics, a company working on the integration of AI and machine learning with clinical diagnostics and flow cytometry, and a member of the Regenerative Medicine Manufacturing Society. She previously held a role at Slingshot Biosciences overseeing marketing, sales, business development, and product management, and is a founding member of BLPN. Her background is in epidemiology and commercial operations.

m•••@generalinception.comreveal

Martin Verhoef· Executive in Residence, Life Science Tools & Dxin

m•••@generalinception.comreveal

Michael Wood· Executive in Residence, Therapeutics

Neil Kubica· Division Lead, Therapeutics· Cambridge, Massachusetts, United Statesin

Neil Kubica is the Therapeutics Division Lead at General Inception. He has worked in the pharmaceutical and biotechnology sectors, with experience in venture capital and scientific advisory roles, and a focus on drug discovery related to the genome.

n•••@generalinception.comreveal

Peter Seufer-Wasserthal· Executive in Residence, Engineered Biology· Austriain

Peter Seufer-Wasserthal is Executive Chair at Planet Smart and Chairman of the Board at Imperagen. He also works as a biotech consultant and serves in board roles, with a background in business development, technology commercialization, life sciences, product portfolio management, and supply chain operations.

Rolando Brawer· Executive in Residence, Life Science Tools & Dx· Encinitas, California, United Statesin

r•••@generalinception.comreveal

Samie Wolfe· Administrative Staff

Sanket Agrawal· Executive in Residence, Therapeutics· Los Angeles Metropolitan Areain

Sanket Agrawal is a biopharma executive with over 20 years of experience across therapeutics and diagnostics, having held roles including general manager of large biopharma units, chief business officer, and CEO of early-stage companies. He has worked across discovery, clinical development, and commercialization, launching drugs, diagnostics, and AI/software platforms, and served as general manager for the industry's first KRAS therapy. He currently works as a business advisor at a stealth-mode biotech company.

Sara Jones· Division Lead, Engineered Biology

s•••@generalinception.comreveal

Soraia Silva Romão· Administrative Staff· Lisbon, Lisbon, Portugalin

Soraia Silva Romão is a Trainee Lawyer at AFMA – Antonio Frutuoso de Melo e Associados, Sociedade de Advogados. Her stated areas of interest include law, health, management, human resources, marketing and communication, consulting, training, and coaching.

Tim Richardson· Strategic Advisor· Gilroy, California, United Statesin

t•••@generalinception.comreveal

Venkat Reddy· Chief Science Officer· Lisbon Metropolitan Areain

Venkat Reddy serves as Chief Scientific Officer at General Inception. His background is in pharmaceutical R&D, with experience in biologic and small molecule drug discovery and the leading of cross-functional and global teams. He has worked across the partnering value chain, including scouting, due diligence and evaluation of biotech and academic institutions, negotiations, and alliance management.

v•••@generalinception.comreveal

Caroline Trant Chambers· CSO· New York, New York, United Statesin

Caroline Trant Chambers works in Investor Partnerships and Capital Formation at Ensemble VC, where she connects the firm's technical team with its capital partners across fund investments, co-investments, and platform services. She previously worked with institutional investors and consultants at Vista Equity Partners' private equity platform and managed private investment deal flow for J.P. Morgan's institutional family office clients.

Mourad Yesayan· Board Member· Washington, District of Columbiain 𝕏

Mourad Yesayan is a Managing Director at Paladin Capital Group and an investment lead for the firm's Cyber Fund, which backs early-stage cybersecurity and digital resilience companies in the US and Europe. He joined Paladin in 2009, having previously served as VP of Finance and a corporate officer at a Nasdaq-listed industrial infrastructure company and as a senior consultant at an M&A and restructuring advisory firm. He holds an MBA and a BS in Finance from Fresno State University.

François Valencony· Chief Business Officer· Caluire-et-Cuire, Auvergne-Rhône-Alpes, Francein

Founder mafia

The GENERAL INCEPTION mafia →

6 people who came through GENERAL INCEPTION went on to found or lead other companies.

Byron HewettExecutive in Residence, Life Science Tools & DxFounded Brava Diagnostics +1 Venkat ReddyChief Science OfficerFounded Enable Medicine Brad NelsonDivision Lead, Life Science Tools & DxFounded Enable Medicine Jeff RiegerExecutive in Residence, Life Science Tools & DxFounded Cryoveritas Jeff CaputoExecutive in Residence, Life Science Tools & DxFounded ClearCut Surgical David FerrickExecutive in Residence, Engineered BiologyFounded Cellsonics

What they invest in

from 35 of 42 portfolio companies

Biotech ×29Deep Tech ×22Medical Devices ×13Healthtech ×10AI & Machine Learning ×7Digital Health ×5Cleantech ×4Hardware ×4

HQs:United States×12France×3Spain×1

Who they back

founder profiles across 13 portfolio companies

15%

solo founders

2 of 13 mapped founding teams

22%

repeat founders

of 18 founders with career history

Founding team size:solo founder×22 founders×63 founders×34+ founders×2

Where their founders studiedfrom 18 founders with education data

Harvard University ×4Harvard Medical School ×3HEC Paris ×3Harvard Business School ×2Universitat Politècnica de Catalunya ×2

What their founders studiedfrom 18 founders with field-of-study data

Life Sciences ×8Engineering ×5Physics ×4Chemistry ×2Computer Science ×2Medicine ×2

Where their founders worked beforefrom 18 founders with career history

Wyss Institute for Biologically Inspired Engineering ×3KU Leuven ×2KU Leuven and VIB ×2Massachusetts General Hospital ×2The University of Tokyo ×2Trellis ×2

Investments · 42 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 1 2024 · 2 2023 · 1 2022 · 16 dated

Switchbacksysswitchbacksys.com inAug 2024✓ verified

Switchback Systems develops a benchtop DNA synthesis platform that combines onboard oligonucleotide synthesis and gene assembly, aimed at putting synthetic biology tools directly in scientists' hands.

BiotechDeep TechHardwareSan Francisco Bay Area, US

Mary Noe(Executive Officer, Director)in

BoardTimothy Richardson(Director)Paul Conley(Director)inA Craig Asher(Director)

Board seatCraig Asher· per SEC Form D

Co-investorsAhren Innovation Capital Vertical Venture Partners OMX Ventures

Biocellisbiocellis.com in✓ verified

Biocellis develops a patented bioluminescence immunoassay platform that delivers laboratory-grade, picogram-level sensitivity with results in under 60 seconds in a compact, portable format for point-of-care and high-throughput screening.

BiotechDeep TechMedical DevicesGrenoble, FR

Vincent Poher(Co-founder)inThierry Rose(Co-founder)Sophie Goyard(Co-founder)

Inapillinapill.com✓ verified

Inapill develops first-in-class, orally available small-molecule therapeutics that target immune cell metabolism to suppress multiple pro-inflammatory cytokines at once.

BiotechDeep TechHealthtech

Greg Timblin(Founder & CEO)inEric Noel(Head of Operations)Kathleen Pestal(Head of Research)

Brainbox Solutionsbrainboxinc.com inNov 2023SEC filingmedium confidence

BRAINBox Solutions develops a multi-modality diagnostic approach for mild traumatic brain injury (mTBI), combining blood biomarker panels with tablet-based neurocognitive testing to produce an objective injury score and a prognosis of post-injury symptoms.

AI & Machine LearningBiotechDigital HealthMedical DevicesHouston, US

Steve Wallace(Chief Operating Officer, Global Supply Chain Management)inDonna J. Edmonds(CEO)inJames V. Snider(Chief Technology Officer / Advisor)Tim Van Meter(Chief Scientific Officer)Richard Noel(Chief Product and Commercial Officer)inRobert Sledd(Director)

Board seat Vikram Chaudhery· per SEC Form D · $18.5M raise · filed Nov 2023

Co-investorsAmbit Health Ventures Bioventures Investors Genoa Ventures VTC Ventures

Glyphic Biotechnologiesglyphic.bio in 𝕏Feb 2024SEC filingmedium confidence

Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.

BiotechDeep TechBerkeley, US

Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)in

BoardJimmy Yun(Director)in

Board seatCraig Asher· per SEC Form D · $52.9M raise · filed Feb 2024

Co-investorsArtis Ventures Black Flag Civilization Ventures Management, Llc FoundersX Ventures Harpoon Ventures LongeVC +5 more

Simbiosyssimbiosys.com in 𝕏Jan 2025SEC filingmedium confidence

SimBioSys builds AI-powered 3D visualization and diagnostic technology that models tumors as "digital twins" to support individualized cancer treatment planning.

AI & Machine LearningBiotechDigital HealthMedical DevicesChicago, US

Joe Peterson(Co-founder)John Cole(Co-founder)Tushar Pandey(Co-founder)in Stacey Stevens(Executive Officer, Director)in

BoardLucy Coassin(Director)

Board seat Vikram Chaudhery· per SEC Form D · $8M raise · filed Jan 2025

Co-investorsAV8 Ventures Genoa Ventures Northpond Ventures

Abbelightabbelight.com in

Abbelight provides microscopy equipment, reagents, and services to researchers and biotech labs for studying biology at the molecular level.

BiotechDeep TechHardwareMedical Devices

Jean-Baptiste Marie(CEO and Co-founder)inNicolas Bourg(CTO and Co-founder)in

BoardSandrine Lévèque-Fort(Scientific Advisor)Emmanuel Fort(Scientific Advisor)

Co-investorsAvant Bio Dynamk Capital

Alida Bioalidabio.com in

Alida Biosciences develops tools for RNA modification detection and analysis that enable research and diagnostic applications across drug discovery, clinical testing, and biotechnology.

AI & Machine LearningBiotechData & InfrastructureDeep TechHealthtechSan Diego, US

Byron Purse(Co-Founder)in John Drewry(Director)inGudrun Stengel(CEO & Co-Founder)

Co-investorsFusionX Ventures Vertical Venture Partners Paladin Capital Group

Axoiyabioaxoiyabio.com

Axoiya Bio develops phosphotyrosine enrichment reagents using proprietary superbinder technology to detect rare, low-abundance phosphorylation events for deeper phosphoproteome coverage.

BiotechDeep Tech

Basilard BioTechbasilardbiotech.com in

Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers.

BiotechDeep TechMedical Devices

Co-investorsBand of Angels Paladin Capital Group Vertical Venture Partners

ClearCut Surgicalclearcutsurgical.com in

Clearcut Surgical develops a surgical device that combines electrosurgery, continuous smoke evacuation, and on-demand fluid suction in a single instrument.

HardwareHealthtechMedical DevicesBoston, US

Alex Yang(MD)inHeung Bae Kim(MD)Jeffery John Caputo(Executive Officer, Director)

Co-investorsLaunchpad Venture Group MassVentures

Constructive Bioconstructive.bio in 𝕏

Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.

BiotechDeep TechNew Materials

Jason Chin(Professor)

Co-investors+ND Capital Amadeus Capital Partners Fine Structures Ventures LongeVC OMX Ventures Paladin Capital Group +3 more

Cryoveritascryoveritas.com in

CryoVeritas makes user-activated temperature indicators that integrate both time and temperature to confirm the integrity of vaccines and biospecimens exposed to heat during cold-chain storage down to −200 °C.

BiotechHardwareHealthtech

Co-investorsPaladin Capital Group

Detectivebiodetectivebio.com

Detective Biosciences is developing a blood-based cancer detection test that analyzes patients' DNA epigenetic profiles.

BiotechHealthtechMedical Devices

Dyno Therapeuticsdynotx.com in 𝕏

Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.

AI & Machine LearningBiotechWatertown, US

Eric Kelsic(CEO & Cofounder)in Sam Sinai(Vice President, Head of ML & Cofounder)in Adrian Veres(Chief Scientific Officer & Cofounder)in George Church(Scientific Cofounder, SAB)in Tomas Bjorklund(Scientific Co-founder, SAB)in Alan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)

Co-investorsAndreessen Horowitz CRV (Charles River Ventures)GV (Google Ventures)Lux Capital Obvious Ventures Casdin Capital +2 more

Elenihealthelenihealth.com in

Eleni Health develops medical devices for female pelvic health treatment, combining neuromodulation and digital health technologies.

Digital HealthFemTechMedical Devices

Stephanie Prendergast(CEO & Co-founder)

Ennovatetxennovatetx.com

Ennovate Pharma is an early-stage biotech company developing personalized therapeutic antibodies for autoimmune and inflammatory diseases, focusing on refractory and non-responder patients of current cytokine-based treatments.

AI & Machine LearningBiotechMedical DevicesSaint-Louis, FR

Exodigmexodigm.com

Exodigm develops extracellular organic sensors that monitor the intracellular genomic and transcriptomic content of living cells, allowing researchers to select, track, and study specific cells by their genomic content.

BiotechDeep TechMedical Devices

Hao Yan(Co-founder)Rizal Hariadi(Co-founder)

Hermes Bioscienceshermesbiosciences.com in

Hermes Biosciences develops a benchtop extracellular vesicle isolation system that purifies exosomes from bodily fluids and cell culture media for research and clinical applications in oncology, degenerative disease, and regenerative medicine.

BiotechDeep TechMedical Devices

Co-investorsPaladin Capital Group Genoa Ventures

Jounce Therapeuticsjouncetx.comAcquired

Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.

BiotechCambridge, US

Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)

Board Robert Tepper(Director)in Cary Pfeffer(Director)inRobert Kamen(Director)in

Co-investorsBoutique Venture Partners Nextech Invest Sofinnova Ventures Venture Capital Investment Management Third Rock Ventures

Kindbodykindbody.com in 𝕏

Kindbody is a fertility care provider offering services such as egg freezing, IVF, IUI, and prenatal and gynecological care through its own clinics across the US.

Digital HealthFemTechHealthtechSan Francisco, US

Dr. Lynn Westphal(Co-founder)Gina Bartasi(Executive Officer, Director)in Fahimeh Sasan(Founding Physician / Ob-Gyn)inAngeline Beltsos, M.D.(Director)

Board Kathy Harris(Director)inCheryl Pegus(Director)

Co-investorsAnsa Capital Claritas Capital GV (Google Ventures)Spice Capital TMV Tq Ventures Llc +3 more

Komo Bioscienceskomobiosciences.com in

KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies.

BiotechDeep Tech

Jennifer Manning(Founder & CEO)inThomas Page(Acting CTO)inMatt Farabaugh(Acting CFO)Jesse B. Owens(Acting CSA)in

BoardRay Tabibiazar(Chairman of the Board)in

Co-investorsGenesis BioCapital Eshelman Ventures, LLC Modi Ventures LDV Partners

Originpeptidesoriginpeptides.com in

Origin Peptides develops an environmentally efficient process for peptide synthesis using aqueous, single-pot reactions that eliminate the need for hazardous organic solvents.

BiotechCleantechDeep TechNew Materials

Dr Sara ten Have(Founder, CSO)Gary Buchanan(Founder, COO)

Partillionpartillion.com inDec 2022

Partillion generates cell-cell interaction data using Nanovials that co-localize cells in defined microenvironments to measure signaling, activation, binding, and other responses, with live-cell recovery via standard flow cytometry.

AI & Machine LearningBiotechDeep TechLos Angeles, US

Dino Di Carlo(Director)in Joe de Rutte(Founder)in Eric Moessinger(Director)in

Board Paul Conley(Director)in

Co-investors+ND Capital Paladin Capital Group Vertical Venture Partners

Pharmacelerapharmacelera.com in 𝕏

Pharmacelera develops computational chemistry software and services for drug discovery, using proprietary 3D molecular field descriptors, quantum mechanics, and AI to screen ultra-large chemical libraries and identify novel, synthesizable compounds.

AI & Machine LearningBiotechDeep TechBarcelona, ES

Enric Gibert(Founder)in Enric Herrero(Founder)in

Co-investorsCapital Cell Heran Partners

Planetsmartplanetsmart.co in

Planet Smart develops PlanetSorb, a fully compostable, bio-based superabsorbent polymer designed to replace fossil-based materials in hygiene products like diapers and menstrual pads.

Circular EconomyCleantechImpact & Social GoodNew Materials

GeraldMaurice

Roxbiosensroxbiosens.com

Roxbiosens develops sequencing-independent tools that analyze complex ecosystems such as the gut microbiome by measuring their bioenergetic status.

BiotechDeep TechDigital Health

Scellgenscellgen.com

sCellgen develops tools for epigenomics research, focused on multiplexed analysis of chromatin modifications and gene expression at the single-cell level.

BiotechDeep TechHealthtech

Surf Therapeuticssurftherapeutics.com inMar 2026 · $6M

Surf Therapeutics develops a non-invasive broad-beam ultrasound platform that stimulates nerves to activate the body's cholinergic anti-inflammatory pathway, aiming to restore immune balance and treat inflammatory and autoimmune disorders without drugs.

Deep TechHealthtechMedical Devices

Co-investorsCapital Factory TMC Venture Fund SOSV VVP Ignite

Synthbiomesynthbiome.com

SynthBiome designs synthetic growth media that replicate the physiological conditions bacterial pathogens encounter in human infection sites, including media mimicking cystic fibrosis sputum and chronic wound environments.

BiotechDeep TechHealthtech

Sam Brown(Founder)in

Tactiletxtactiletx.com

Tactile Therapeutics is a venture-funded biotechnology company working on Targeted Protein Degradation.

Biotech

Taviratxtaviratx.com in

Tavira Therapeutics develops an AAV delivery platform for gene therapy that uses modular, post-manufacture enzymatic modification of AAV vectors to target intended tissues more accurately.

BiotechDeep TechMedical Devices

Els Henckaerts(Co-founder)Benjamien Moeyaert(Co-founder)inVeronick Benoy(Co-founder)inVibha Kiran Tamboli(Co-founder)Inge Van Hove(Co-founder)in

Trenchtxtrenchtx.com

Trench Therapeutics develops live biotherapeutic products derived from research on the nasal microbiome to prevent and treat infectious and inflammatory diseases.

BiotechHealthtech

Cindy Liu(Co-founder)David Harburger(Co-founder)Prashant Girinath(Co-founder)

Wespranwespran.com in

Wespran develops biotechnology that converts industrial CO2 emissions into valuable chemicals like green methanol using engineered enzymes, serving heavy industries such as refineries and steel plants.

BiotechCleantechClimate TechDeep Tech

Xeraenergyxeraenergy.com

XEra Energy develops separation and purification methods for processing critical minerals and recycling lithium-ion batteries, targeting regions with gaps in scalable, profitable processing capabilities.

Circular EconomyCleantechDeep TechEnergyNew MaterialsSan Francisco, US

Dr. Haixia Deng(Founder & CEO)Dr. Wenlong Yao(COO-Founding Member)

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AccelmedxBase Pair BiologyBreathwalkGeneralinceptiontxIgniter ManagementNema TherapeuticsXCUR Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Portfolio news

latest coverage across their companies

Surf Therapeutics Receives Investment from Jetstream Venture Fund

Surf Therapeutics · finsmes.com · Apr 13, 2026

Pharmacelera raises $6m to advance AI drug discovery - Drug Discovery World (DDW)

Pharmacelera · ddw-online.com · Feb 20, 2026

MedTech Week 4 - Regulatory momentum, capital deployment, and execution-focused leadership

ClearCut Surgical · gscapitalconnect.substack.com · Jan 26, 2026

Abbelight Raises Series B Funding

Abbelight · finsmes.com · Jan 8, 2026

Editor’s pick: Constructive Bio | Nature Biotechnology

Constructive Bio · nature.com · Oct 20, 2025

The Top Five Emerging Startups Harnessing Single Cell Sequencing | Inside Precision Medicine

Partillion · insideprecisionmedicine.com · Jun 9, 2025

Frequently asked questions

How many investments has GENERAL INCEPTION made?: GENERAL INCEPTION has 42 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.
What stage does GENERAL INCEPTION invest at?: GENERAL INCEPTION invests at the Pre-Seed, Seed stages.
What sectors does GENERAL INCEPTION focus on?: GENERAL INCEPTION focuses on Biotech, Deep Tech, Medical Devices, Sector Agnostic.
Where is GENERAL INCEPTION located?: GENERAL INCEPTION is headquartered in Palo Alto, US.
Does GENERAL INCEPTION lead rounds?: GENERAL INCEPTION typically participates in rounds rather than leading them.
Who does GENERAL INCEPTION co-invest with?: GENERAL INCEPTION most often shares deals with Paladin Capital Group, Vertical Venture Partners, GV (Google Ventures), among 29 tracked co-investors.

Images

Co-investors · 2

Northpond Ventures

Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.

Both backed · 1

Simbiosys

$100K – $5M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

$50K – $250M

Firms observed investing alongside GENERAL INCEPTION, from public investor directories. Shared companies are the overlap with GENERAL INCEPTION's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

$500K – $15M

Draper Associates

Draper Associates is an early-stage venture firm that backs bold, visionary founders building transformational businesses ahead of mainstream conviction.

$500K – $5M

Qbic Fund

Qbic is an inter-university venture capital fund that turns technological breakthroughs from its partner universities, research institutes and hospitals into sustainable businesses.

Radar Ventures

Radar Ventures is a private fund based in Australia and New Zealand that invests globally in early-stage deep tech and platform technologies aimed at solving large-scale global problems.